[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508464":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":57,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":30,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":30,"enrollmentInfo":73,"targetDuration":30,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":39,"whyStopped":30,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Zimberelimab combined with or without AVD sequential radiotherapy","EXPERIMENTAL","1. Combination therapy： Subjects received Zimberelimab 240mg Q3W 2 cycle.\n\n   According to the results of PET\u002FCT evaluation:\n\n   CR: Additional 2 cycles of Zimberelimab (4 cycles of Zimberelimab monotherapy in total); PR: 2 cycles of Zimberelimab+ AVD therapy (only PR patients combined with AVD). Subjects who did not achieve a Partial Response (PR) or Complete Response (CR) in their initial or subsequent efficacy evaluations, and whose potential for benefit was deemed unlikely by the investigator, were discontinued from the study.\n2. Radiotherapy treatment period (patients with CR\u002FPR): Sequentially radiation therapy 20-30Gy.",[13],"Drug: Zimberelimab 240mg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Zimberelimab 240mg","AVD regimen:\n\nDoxorubicin 25mg\u002Fm2, d1, d15, IV; Vincristine 3mg\u002Fm2, d1, d15 IV; Dacarbazine 0.375mg\u002Fm2, d1, d15 IV",[9],[21],"GLS-010",[23],{"name":24,"affiliation":5,"role":25},"Zhiming Li","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","+8613719189172",null,"lizhm@sysucc.org.cn",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Yu Wang","+86-20-87343765","wangyu@sysucc.org.cn",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Department of Medical Oncology, Sun Yat-Sen University Cancer Center","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":46,"coordinates":47},"Point",[48,49],113.25,23.11667,{"lat":49,"lon":48},[52,55],{"name":53,"role":28,"phone":54,"phoneExt":30,"email":31},"Zhiming Li, MD","+86-13719189172",{"name":56,"role":28,"phone":34,"phoneExt":30,"email":35},"Yu Wang, MD",{"type":25,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Li Zhiming","Professor",[61],{"name":62,"class":63},"Guangzhou Gloria Biosciences Co., Ltd.","INDUSTRY","100508464","phase-2-a-study-of-zimberelimabgls-010-combined-with-avd-for-newly-diagnosed-early-stage-hodgkins-lymphoma-100508464",false,"NCT05900765","A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma","A Multicenter, Open-label Phase II Study on the Treatment of Newly Diagnosed Early-stage Hodgkin's Lymphoma With Zimberelimab (GLS-010) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET\u002FCT","Inclusion Criteria:\n\n1. Diagnosed with primary classical Hodgkin lymphoma (HL) based on histopathology.\n2. Stage I-II .\n3. At least one measurable target lesion（Lugano 2014）.\n4. Age 18 years or older (including 18 years) to 45 years (recent fertility requirements and concern about chemotherapy side effects), or age \\>60 years (older patients who are frail and unwilling to undergo chemotherapy), male or female.\n5. ECOG PS 0-3,\n6. Expected survival ≥ 3 months.\n\nExclusion Criteria:\n\n1. Hodgkin's lymphoma with nodular lymphocyte predominant type.\n2. Patients who are scheduled to undergo subsequent autologous stem cell transplantation.\n3. Contraindications to radiotherapy.\n4. With central nervous system (meningeal or parenchymal) involvement.\n5. Contraindications to immune checkpoint inhibitors.","ALL","18 Years",{"count":74,"type":75},54,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","This is a multicenter, open-label single-arm phase II study to evaluate the efficacy and safety of Zimberelimab (GLS-010) combined with AVD for newly diagnosed early-stage Hodgkin's lymphoma under the guidance of PET\u002FCT.",[81],"Classical Hodgkin Lymphoma",[83,84,85],"Zimberelimab","PD-1 Checkpoint Inhibitor","AVD","2023-06-15",{"date":88,"type":89},"2023-06-18","ACTUAL",{"date":91,"type":89},"2023-06-14",{"date":93,"type":75},"2026-06-30",{"name":5,"class":6},1]